99 related articles for article (PubMed ID: 24054565)
1. Development and validation of a general approach to predict and quantify the synergism of anti-cancer drugs using experimental design and artificial neural networks.
Pivetta T; Isaia F; Trudu F; Pani A; Manca M; Perra D; Amato F; Havel J
Talanta; 2013 Oct; 115():84-93. PubMed ID: 24054565
[TBL] [Abstract][Full Text] [Related]
2. Mixed copper-platinum complex formation could explain synergistic antiproliferative effect exhibited by binary mixtures of cisplatin and copper-1,10-phenanthroline compounds: An ESI-MS study.
Pivetta T; Lallai V; Valletta E; Trudu F; Isaia F; Perra D; Pinna E; Pani A
J Inorg Biochem; 2015 Oct; 151():107-14. PubMed ID: 26021964
[TBL] [Abstract][Full Text] [Related]
3. Determination of drug synergism between the tyrosine kinase inhibitors NSC 680410 (adaphostin) and/or STI571 (imatinib mesylate, Gleevec) with cytotoxic drugs against human leukemia cell lines.
Avramis IA; Laug WE; Sausville EA; Avramis VI
Cancer Chemother Pharmacol; 2003 Oct; 52(4):307-18. PubMed ID: 12827297
[TBL] [Abstract][Full Text] [Related]
4. Role of glutathione in the in vitro synergism between 4-hydroperoxy-cyclophosphamide and cisplatin in leukemia cell lines.
Peters RH; Jollow DJ; Stuart RK
Cancer Res; 1991 May; 51(10):2536-41. PubMed ID: 2021933
[TBL] [Abstract][Full Text] [Related]
5. Mixed-1,10-phenanthroline-Cu(II) complexes: synthesis, cytotoxic activity versus hematological and solid tumor cells and complex formation equilibria with glutathione.
Pivetta T; Isaia F; Verani G; Cannas C; Serra L; Castellano C; Demartin F; Pilla F; Manca M; Pani A
J Inorg Biochem; 2012 Sep; 114():28-37. PubMed ID: 22687563
[TBL] [Abstract][Full Text] [Related]
6. In vitro anti-tumour effect of 1,10-phenanthroline-5,6-dione (phendione), [Cu(phendione)3](ClO4)2.4H2O and [Ag(phendione)2]ClO4 using human epithelial cell lines.
Deegan C; Coyle B; McCann M; Devereux M; Egan DA
Chem Biol Interact; 2006 Dec; 164(1-2):115-25. PubMed ID: 17030029
[TBL] [Abstract][Full Text] [Related]
7. Design and sample size for evaluating combinations of drugs of linear and loglinear dose-response curves.
Fang HB; Tian GL; Li W; Tan M
J Biopharm Stat; 2009 Jul; 19(4):625-40. PubMed ID: 20183430
[TBL] [Abstract][Full Text] [Related]
8. Enhancement of 5-fluorouracil cytotoxicity by cisplatin in brain tumour cell lines.
Mineura K; Kowada M
Cell Biol Int; 1996 May; 20(5):355-7. PubMed ID: 8688852
[TBL] [Abstract][Full Text] [Related]
9. Probenecid is a chemosensitizer in cancer cell lines.
Campos-Arroyo D; Martínez-Lazcano JC; Melendez-Zajgla J
Cancer Chemother Pharmacol; 2012 Feb; 69(2):495-504. PubMed ID: 21861129
[TBL] [Abstract][Full Text] [Related]
10. Enhancement of trimetrexate cytotoxicity in vitro and in vivo by carboxypeptidase G2.
Romanini A; Sobrero AF; Chou TC; Sherwood RF; Bertino JR
Cancer Res; 1989 Nov; 49(21):6019-23. PubMed ID: 2529027
[TBL] [Abstract][Full Text] [Related]
11. Synergistic anticancer activity of Thiazolo[5,4-b]quinoline derivative D3CLP in combination with cisplatin in human cervical cancer cells.
González-Sánchez I; Lira-Rocha A; Navarrete A; Loza-Mejía MA; Coronel-Cruz C; Mendoza-Rodríguez CA; Cerbón MA
Anticancer Res; 2012 Dec; 32(12):5159-65. PubMed ID: 23225412
[TBL] [Abstract][Full Text] [Related]
12. In vitro validation of gamma-secretase inhibitors alone or in combination with other anti-cancer drugs for the treatment of T-cell acute lymphoblastic leukemia.
De Keersmaecker K; Lahortiga I; Mentens N; Folens C; Van Neste L; Bekaert S; Vandenberghe P; Odero MD; Marynen P; Cools J
Haematologica; 2008 Apr; 93(4):533-42. PubMed ID: 18322257
[TBL] [Abstract][Full Text] [Related]
13. Measuring and modeling of binary mixture effects of pharmaceuticals and nickel on cell viability/cytotoxicity in the human hepatoma derived cell line HepG2.
Rudzok S; Schlink U; Herbarth O; Bauer M
Toxicol Appl Pharmacol; 2010 May; 244(3):336-43. PubMed ID: 20132835
[TBL] [Abstract][Full Text] [Related]
14. Neighbor communities in drug combination networks characterize synergistic effect.
Zou J; Ji P; Zhao YL; Li LL; Wei YQ; Chen YZ; Yang SY
Mol Biosyst; 2012 Oct; 8(12):3185-96. PubMed ID: 23014807
[TBL] [Abstract][Full Text] [Related]
15. Enhancement of lexatumumab-induced apoptosis in human solid cancer cells by Cisplatin in caspase-dependent manner.
Wu XX; Kakehi Y
Clin Cancer Res; 2009 Mar; 15(6):2039-47. PubMed ID: 19276256
[TBL] [Abstract][Full Text] [Related]
16. The evaluation of gastric cancer sensitivity to 5-FU/CDDP in terms of induction of apoptosis: time- and p53 expression-dependency of anti-cancer drugs.
Matsuhashi N; Saio M; Matsuo A; Sugiyama Y; Saji S
Oncol Rep; 2005 Sep; 14(3):609-15. PubMed ID: 16077963
[TBL] [Abstract][Full Text] [Related]
17. Synergistic effects of ICI 182,780 on the cytotoxicity of cisplatin in cervical carcinoma cell lines.
García-López P; Rodríguez-Dorantes M; Pérez-Cárdenas E; Cerbón M; Mohar-Betancourt A
Cancer Chemother Pharmacol; 2004 Jun; 53(6):533-40. PubMed ID: 15138713
[TBL] [Abstract][Full Text] [Related]
18. Interactions of doxycycline with chemotherapeutic agents in human breast adenocarcinoma MDA-MB-231 cells.
Foroodi F; Duivenvoorden WC; Singh G
Anticancer Drugs; 2009 Feb; 20(2):115-22. PubMed ID: 19209028
[TBL] [Abstract][Full Text] [Related]
19. Synergistic cytotoxicity using 2'-deoxy-5-azacytidine and cisplatin or 4-hydroperoxycyclophosphamide with human tumor cells.
Frost P; Abbruzzese JL; Hunt B; Lee D; Ellis M
Cancer Res; 1990 Aug; 50(15):4572-7. PubMed ID: 1695122
[TBL] [Abstract][Full Text] [Related]
20. Synergistic anti-cancer effects of silibinin with conventional cytotoxic agents doxorubicin, cisplatin and carboplatin against human breast carcinoma MCF-7 and MDA-MB468 cells.
Tyagi AK; Agarwal C; Chan DC; Agarwal R
Oncol Rep; 2004 Feb; 11(2):493-9. PubMed ID: 14719089
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
